Citations
2 citation(s) found for "Wang, Tian".
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
Hajnik, Renee L. , Plante, Jessica A. , Liang, Yuejin , Alameh, Mohamad‐Gabriel , Tang, Jinyi , Bonam, Srinivasa Reddy , Zhong, Chaojie, Adam, Awadalkareem, Scharton, Dionna , Rafael, Grace, Liu, Yang , Hazell, Nicholas C., Sun, Jiaren , Shi, Pei‐Yong , Wang, Tian , Walker, David H. , Plante, Kenneth S. , Soong, Lynn , Shi, Pei-Yong , Wang, Tian , Sun, Jie , Weissman, Drew , Weaver, Scott C , Plante, Kenneth S , Hu, Haitao , Tang, J , Liu, Yang , Sun, Jie
Science Translational Medicine | September 14, 2022 | Volume: 14 | Issue: 662 | Pages: No page available
10.1126/scitranslmed.abq1945
| PMID 36103514
Emergence of SARS-CoV-2 variants of concern (VOCs), including the highly transmissible Omicron and Delta strains, has posed constant challenges to the current COVID-19 vaccines that principally target the viral spike protein (S). Here, we report a nucleoside-modified messenger RNA (mRNA) vaccine that expresses the more conserved viral nucleoprotein (mRNA-N) and show that mRNA-N vaccination alone can induce modest control of SARS-CoV-2. Critically, combining mRNA-N with the clinically proven S-expressing mRNA vaccine (mRNA-S+N) induced robust protection against both Delta and Omicron variants. In the hamster models of SARS-CoV-2 VOC challenge, we demonstrated that, compared to mRNA-S alone, combination mRNA-S+N vaccination not only induced more robust control of the Delta and Omicron variants in the lungs but also provided enhanced protection in the upper respiratory tract. In vivo CD8 + T cell depletion suggested a potential role for CD8 + T cells in protection conferred by mRNA-S+N vaccination. Antigen-specific immune analyses indicated that N-specific immunity, as well as augmented S-specific immunity, was associated with enhanced protection elicited by the combination mRNA vaccination. Our findings suggest that combined mRNA-S+N vaccination is an effective approach for promoting broad protection against SARS-CoV-2 variants.
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, Joshua D. , Li, Lu , Wang, Yuxuan , Thoburn, Christopher J. , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A. , Wong, Fay , Mattox, Austin K. , Hruban, Ralph H. , Wolfgang, Christopher L. , Molin, Marco Dal , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Browne, J. Dale, Tie, Jeanne , Wong, Hui‐Li , Mansfield, Aaron S. , Jen, Jin , Falconi, Massimo , Allen, Peter J. , Zhou, Shibin , Díaz, Luis A. , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Thoburn, Christopher , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A , Wong, Fay , Mattox, Austin , Wolfgang, Christopher L , Roden, Richard , Klein, Alison P , Ptak, Janine , Dobbyn, Lisa , Schaefer, Joy , Silliman, Natalie , Schoen, Robert E , Brand, Randall E , Tie, Jeanne , Wong, Hui-Li , Mansfield, Aaron S , Jen, Jin , Zhou, Shibin , Diaz, Luis A , Tomasetti, Cristian , Kinzler, Kenneth W , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Wang, Yuxuan , Afsari, Bahman , Goggins, Michael , Wang, Tian‐Li , Klein, Alison P. , Popoli, Maria , Vogelstein, Joshua T , Schoen, Robert E. , Brand, Randall E. , Gibbs, Peter , Hanash, Samir , Bettegowda, Chetan , Massimo, Falconi
Science | January 18, 2018 | Volume: 359 | Issue: 6378 | Pages: 926-930
10.1126/science.aar3247
| PMID 29348365
SEEK and you may find cancer earlier Many cancers can be cured by surgery and/or systemic therapies when detected before they have metastasized. This clinical reality, coupled with the growing appreciation that cancer's rapid genetic evolution limits its response to drugs, have fueled interest in methodologies for earlier detection of the disease. Cohen et al. developed a noninvasive blood test, called CancerSEEK that can detect eight common human cancer types (see the Perspective by Kalinich and Haber). The test assesses eight circulating protein biomarkers and tumor-specific mutations in circulating DNA. In a study of 1000 patients previously diagnosed with cancer and 850 healthy control individuals, CancerSEEK detected cancer with a sensitivity of 69 to 98% (depending on cancer type) and 99% specificity. Science , this issue p. 926 ; see also p. 866